Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy

  • Research Article
  • Published:
Tumor Biology

This article was retracted on 20 April 2017

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified human oncoprotein that can stabilize some proteins by inhibiting degradation mediated by protein phosphatase 2A (PP2A), and its level in cancer is associated with resistance to chemotherapy. However, whether CIP2A could increase chemoresistance of prostate cancer (PCa) cells to chemotherapeutic agent cabazitaxel remains unclear. To determine whether CIP2A serves as a potential therapeutic target of human PCa, we utilized small interference RNA (siRNA) to knock down CIP2A expression in human PCa cells and analyzed their phenotypic changes. The data demonstrated that CIP2A was significantly elevated in mCRPC cell lines C4-2 and ARCaPM at both the mRNA and protein levels. CIP2A silencing led to decreased proliferation and enhanced chemosensitivity and apoptosis to cabazitaxel in human PCa cells, as well as reduced Akt phosphorylation. Our data suggesting critical roles of CIP2A in PCa cells chemoresistance to cabazitaxel and raising the possibility of CIP2A inhibition as a promising approach for chemosensitization of metastatic castration-resistant prostate cancer (mCRPC).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  2. Ren SC, Chen R, Sun YH. Prostate cancer research in China. Asian J Androl. 2013;15:350–3.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168(1):9–12.

    Article  PubMed  Google Scholar 

  4. Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2014;6(4):167–79.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lassi K, Dawson NA. Update on castrate-resistant prostate cancer. Curr Opin Oncol. 2010;22:263–7.

    Article  PubMed  Google Scholar 

  6. Tannock I, De Wit R, Berry W, Horti J, Pluzanska A, Chi K, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article  CAS  PubMed  Google Scholar 

  7. Singh P, Yam M, Russell PJ, Khatri A. Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett. 2010;293:1–14.

    Article  CAS  PubMed  Google Scholar 

  8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147–54.

    Article  PubMed  Google Scholar 

  9. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(1):12–23.

    Article  CAS  PubMed  Google Scholar 

  10. Chen M, Nowak DG, Trotman LC. Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. Clin Cancer Res. 2014;20(12):3057–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. 2010;29:6257–66.

    Article  CAS  PubMed  Google Scholar 

  12. Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, et al. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett. 2011;585:755–60.

    Article  CAS  PubMed  Google Scholar 

  13. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54(10):2577–81.

    CAS  PubMed  Google Scholar 

  14. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, et al. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: Implication in human prostate cancer bone metastasis. Oncogene. 2007;26(35):5070–7.

    Article  CAS  PubMed  Google Scholar 

  15. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55(5):300–18. quiz 305-323.

    Article  PubMed  Google Scholar 

  16. Qu YY, Dai B, Kong YY, Ye DW, Yao XD, et al. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl. 2013;15(1):110–5.

    Article  CAS  PubMed  Google Scholar 

  17. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

    Article  CAS  PubMed  Google Scholar 

  18. Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol. 2011;29(27):3686–94.

    Article  CAS  PubMed  Google Scholar 

  19. Keizman D, Maimon N, Gottfried M. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions. Am J Clin Oncol. 2012;37(3):289–96.

    Article  Google Scholar 

  20. Kao SC, Hovey E, Marx G. Second-line therapy for castrate-resistant prostate cancer: a literature review. Asia Pac J Clin Oncol. 2011;7(3):212–23.

    Article  PubMed  Google Scholar 

  21. Lheureux S, Joly F. Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer. Bull Cancer. 2012;99(9):875–80.

    CAS  PubMed  Google Scholar 

  22. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One. 2013;8(10):e75292.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Zhang S, Wang Y, Chen Z, Kim S, Iqbal S, Chi A, et al. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Prostate. 2013;73(15):1681–9.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This study was supported by the grants from the National Natural Science Foundation of China (No. 81202036, 31471033)

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Urology, 85 Hospital of PLA, Shanghai, China

    Jinming Huang, Qiang Tong, Jun Liu, Jun Qiu, Rong Sun & Lixin Yao

  2. Department of Oncology and Hematology, The Second Hospital, Jilin University, Changchun, China

    Jiaoyuan Jia

  3. Department of Urology, Wuxi No.2 People’s Hospital affiliated to Nanjing Medical University, Jiangsu, China

    Chun Yang

Authors
  1. Jinming Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiaoyuan Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiang Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lixin Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Lixin Yao or Chun Yang.

Additional information

Jinming Huang and Jiaoyuan Jia contributed equally to this work.

The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.

An erratum to this article is available at http://dx.doi.org/10.1007/s13277-017-5487-6.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, J., Jia, J., Tong, Q. et al. RETRACTED ARTICLE: Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy. Tumor Biol. 36, 1589–1594 (2015). https://doi.org/10.1007/s13277-014-2748-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2748-5

Keywords

Search

Navigation